Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
| ▸ | TNKS | O95271 | 2/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 15/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700324 | 0.86 | CALCRL (0.56) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL15205127 | 0.85 | TNKS (0.61) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL13351308 | 0.83 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL12655389 | 0.83 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL12402801 | 0.83 | CALCRL (0.55) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL13380149 | 0.82 | CALCRL (0.56) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL14028501 | 0.82 | CALCRL (0.37) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL14046378 | 0.82 | DRD2 (0.56) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL16456308 | 0.82 | TNKS (0.58) | OPRM1OPRD1OPRK1OPRL1TNKS | |
| SCHEMBL14028503 | 0.82 | MAP3K11 (0.39) | OPRM1OPRD1OPRK1OPRL1TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | OPRM1 39/4885OPRD1 63/4885OPRK1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.